Kornimate/medical-research-clean huggingface dataset:
motor imagery plus therapeutic exercise in women with menstrual pain

Conditions: Motor Imagery Training

Summary: the researchers will conduct a study that combines motor imagery with therapeutic exercise in women experiencing menstrual pain. previous research suggests that motor imagery, when used alongside physical exercise, may help improve motor control and alleviate pain, potentially enhancing outcomes for individuals dealing with chronic pain conditions. through this study, the investigators aim to explore the effectiveness of these interventions in targeting key variables such as pain perception, motor coordination, and overall quality of life, building on existing evidence of motor imagery's benefits in pain management.


Eligibility criteria:
inclusion criteria: * women who have experienced menstrual pain for more than 6 months. * pain intensity rated higher than 3/10 on a pain scale. * participants do not take pain-relief medication during the study period. * ages between 18 and 35 years old exclusion criteria: * current use of hormonal contraceptives or other treatments that affect menstrual cycles. * any chronic pain condition unrelated to menstrual pain (e.g., fibromyalgia, chronic low back pain). * diagnosed gynecological conditions such as endometriosis or pelvic inflammatory disease. * pregnancy or breastfeeding. * current use of psychoactive medications that could affect pain perception. * any significant psychiatric condition that could interfere with study participation. * history of recent pelvic surgery (within the last 6 months).

Keywords: motor imagery therapeutic exercise menstrual pain
non-interventional, multicenter bicontact® e pmcf study

Conditions: Degenerative Osteoarthritis; Rheumatoid Arthritis; Femoral Neck Fractures; Femoral Head Necrosis

Summary: prospective observational (non-interventional) cohort study, multi-centric in 5 study centers in japan to collect short term clinical and radiological results of the cementless bicontact® e stem in a standard patient population used in routine clinical practice


Eligibility criteria:
inclusion criteria: * indication for bicontact e prosthesis tha * patients ≥ 18 years * patient not pregnant * written informed consent exclusion criteria: - patients receiving a bipolar implantation

Keywords: arthroplasty, replacement, hip
alkaline ionized water: sports recovery and inflammation management

Conditions: Sports Recovery

Summary: the purpose of this study is to determine whether consumption of alkaline ionized water is effective for accelerating sports recovery.

alkaline ionized water versus tap water is consumed for one week prior to an exercise challenge, using a cross-over study design.

Eligibility criteria:
inclusion criteria: * male * age 25-40 years (inclusive) * body mass index (bmi) between 19.0 and 29.9 kg/m2 (inclusive) * not regularly exercising or participating in team sports. exclusion criteria: * bariatric surgery * diagnosed and medicated for diabetes * known serious chronic health condition * serious active illness within past 12 months * major surgery during past 8 weeks * alcohol consumption of more than four standard units/day (for example more than four regular 12-oz beers (5% alcohol), four small 5-oz glasses of wine (12% alcohol), or four 1.5 oz shots of 80-proof spirits) (or more than 28 per week); * regular use of marijuana products for the past three months * regular consumption of energy drinks * diagnosed with any blood clotting disorder or taking clotting factor concentrates. * taking any blood thinners or anticoagulants * taking anti-inflammatory medications on a daily basis (81 mg aspirin is acceptable) * diagnosed with high blood pressure or taking blood pressure medication * use of performance enhancing drugs within the last three months * having consumed prednisone (or related steroid medication) or received a prednisone injection within the last six months
a study of humanized bcma-targeted car-t cells therapy for refractory/relapsed multiple myeloma

Conditions: Relapse Multiple Myeloma; Refractory Multiple Myeloma

Summary: clinical trial for the safety and efficacy of humanized bcma-targeted car-t cells therapy for refractory/relapsed multiple myeloma

this is a single arm, open-label, single-center study. this study is indicated for relapsed bcma+ multiple myeloma, the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 50 patients will be enrolled for this trial. primary objective is to explore the safety, main consideration is dose-related safety.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of multiple myeloma (mm): 1. patients with bcma positive relapsed/refractory mm; 2. relapsed after hematopoietic stem cell transplantation; 3. cases with recurrent positive minimal residual disease; 4. extramedullary leision which is hard to be eradicated by chemotherapy or radiotherapy. 2. anticipated survival time more than 12 weeks; 3. male or female aged 30-75 years; 4. those who voluntarily participated in this trial and provided informed consent. exclusion criteria: subjects with any of the following exclusion criteria were not eligible for this trial: 1. history of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases; 2. electrocardiogram shows prolonged qt interval, severe heart diseases such as severe arrhythmia in the past; 3. pregnant (or lactating) women; 4. patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis); 5. active infection of hepatitis b virus or hepatitis c virus; 6. concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving in haled steroids; 7. previously treated with any car-t cell product or other genetically-modified t cell therapies; 8. creatinine\>2.5mg/dl, or alt / ast \> 3 times of normal amounts, or bilirubin\>2.0 mg/dl; 9. other uncontrolled diseases that were not suitable for this trial; 10. patients with hiv infection; 11. any situations that the investigator believes may increase the risk of patients or interfere with the results of study.

Keywords: multiple myeloma car t-cell therapy bcma
safety and efficacy of a transvaginal suture capturing mesh device

Conditions: Surgical Repair of Middle Compartment Prolapse (Vaginal Vault or Uterine Prolapse) With or Without Cystocele

Summary: to perform a clinical safety and efficacy assessment of the uphold lite system for pelvic organ prolapse in a prospective multicenter, single cohort study.


Eligibility criteria:
inclusion criteria: * 18 years of age or older and present with primary or recurrent prolapse of the middle vaginal compartment corresponding to stage 2 or higher (according to the pelvic organ prolapse quantification \[pop-q\] system)9, * with or without anterior vaginal wall prolapse, and * experiences symptoms of vaginal bulging with or without a previous hysterectomy * being able to provide oral and written informed consent before entering the study. exclusion criteria: * previous cancer of any pelvic organ, * systemic glucocorticoid treatment, * insulin-treated diabetes, * an inability to participate in study follow-up or to provide informed consent, or * the need for any concomitant pelvic surgery.
clinical improvement due to the home use of agilik in children with cerebral palsy

Conditions: Cerebral Palsy (CP)

Summary: the goal of this clinical trial is to learn if a two month training with the agilik powered orthosis improves the knee extension or the endurance in pediatric patients with cerebral palsy and a crouch gait. it will also learn about the safety of agilik. the main questions it aims to answer are: does the agilik powered orthosis increase the value of the knee extension during walking? what medical problems do participants have when using the agilik powered orthosis? researchers will compare a group of patients using the agilik powered exoskeleton with a group of patients treated with standard therapy. participants will: use agilik at home or perform standard therapy for 2 months visit the clinic at the beginning of the study, after 3 months and after 1 additional month.


Eligibility criteria:
inclusion criteria: * diagnosis of cp and a crouch gait * provision of signed and dated informed consent form. * stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination. * body weight between 20 and 125 kg * knee flexion retraction assessed in supine position by less than 10°. hamstring contracture as assessed by straight leg raising test does not limit ability to participate in the study. * subjects must not have had a tibio-tarsal arthrodesis. in addition, they must have at least 5° of passive dorsi-flexion of the ankle. * able to walk at least 3 m without stopping, with or without a walking aid. * able to understand and follow simple directions based on parent report and physician observation during historical and physical examination. * gmfcs level i, ii and iii * mas score ≤ 2 exclusion criteria: * any severe neurological, musculoskeletal and/or cardiorespiratory involvement preventing the ability to walk; * a history of uncontrolled seizure in the past year * severe spasticity * hip and/or knee flexion contracture of more than 20°

Keywords: exoskeleton device powered orthosis cerebral palsy crouch gait home use
a phase ib/ii clinical study of shr-9839 for injection combined with other anti-tumor therapies in patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this study is an open-label, multicenter phase ib/ii clinical trial to evaluate the safety, tolerability and efficacy of shr-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. aged 18-75 years old (inclusive), regardless of gender. 2. patients with locally advanced or metastatic solid tumors confirmed by histology or cytology,. 3. at least one measurable tumor lesion according to recist v1.1. 4. ecog performance score of 0-1. 5. life expectancy ≥ 12 weeks. 6. adequate bone marrow and organ function. 7. have the ability to informed consent, have signed the irb / ec approved informed consent and dated, willing and able to comply with the treatment plan to visit the inspection and other procedural requirements. exclusion criteria: 1. patients with active central nervous system ( cns ) metastases. 2. spinal cord compression not be cured by surgery or radiotherapy. 3. subjects with uncontrollable tumor-related pain. 4. clinically uncontrollable the third space effusion. 5. anti-tumor treatments such as chemotherapy within 4 weeks prior to the first dose of study drug. 6. received \> 30gy chest radiotherapy within 24 weeks prior to the first dose of study drug. 7. major organ surgery or significant trauma within 4 weeks prior to the first dose of study drug. 8. concomitant other malignancies ≤ 3 years prior to the first dose of study drug. 9. history of interstitial pneumonitis or imaging at screening suggestive of suspected interstitial pneumonitis or inability to exclude interstitial pneumonitis; or other moderate-to-severe lung disease that severely affects lung function. 10. serious cardiovascular and cerebrovascular diseases. 11. patients with clinically significant bleeding symptoms within 3 months prior to the first dose of study drug. 12. history of immunodeficiency, including hiv test positive. 13. active hepatitis b or hepatitis c infection. 14. history of severe allergic reactions to any component of any study drug to be accepted. 15. known history of alcohol or drug dependence. 16. mental disorders or poor compliance ; 17. pregnant or lactating women.
mindfulness and yoga for pain with interstitial cystitis evaluation

Conditions: Interstitial Cystitis

Summary: this study is examining impact of pain on daily life, the ability to function and treatments used for patients with interstitial cystitis/painful bladder syndrome before and after a program of mindfulness and yoga, in comparison to patients who are undergoing treatment with their providers.

this is a randomized control trial comparing women diagnosed with interstitial cystitis/painful bladder syndrome (icpbs) receiving usual icpbs care to those treated with usual care supplemented with meditation and yoga. both groups continued their current icpbs treatment regimens. participants in the intervention group additionally received a commercially available meditation application and a yoga tutorial video. women in either group were followed weekly for three months. validated questionnaires were used to compare treatment response from baseline to 12 weeks of intervention for both groups. the primary outcome was the patient report on the global response assessment (gra), and we required a sample size of 82 patients (41 per group) to detect a difference of 30% with a 10% margin of error (alpha of 0.05) with 80% power. other questionnaires collected included the promis pain interference scale, the interstitial cystitis problem index and symptom index (icpi and icsi), the vas pain scale, treatment compliance, and treatment escalation.

Eligibility criteria:
inclusion criteria: * female * \>=age 18 * ic/bps diagnosis * english or spanish reading/writing * own a smartphone and able to watch online yoga tutorials * ability/willingness to participate in follow up questionnaires * icsi/icpi \>6 at baseline * physical exam in the past 2 years by urogynecology or gynecologist exclusion criteria: * pregnancy or lactating * inability to speak/write in english/spanish * known history of recurrent uti * urinary retention ( pvr\>150 ml) * history of augmentation cystoplasty or urinary diversion. * history of chemotherapy/radiation or radiation induced cystitis * hunner's ulcers demonstrated in last 6 months by cystoscopy * parkinsonism with neurogenic bladder * multiple sclerosis with neurogenic bladder * cva with residual deficits * patients with severe mobility impairment and inability to perform yoga postures * patients who are hard of hearing or visually impaired * imprisoned patients

Keywords: interstitial cystitis complementary and alternative medicine yoga meditation
relief - a global prospective observational post-market study to evaluate long-term effectiveness of neurostimulation therapy for pain

Conditions: Pain

Summary: to compile characteristics of real-world clinical outcomes for boston scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable directions for use - and - to evaluate the economic value and technical performance of boston scientific commercially approved neurostimulation systems for pain in routine clinical practice

the study is a prospective, multi-center, global registry of boston scientific neurostimulation systems for pain. the study treatment will consist of neurostimulation trial therapy with any commercially approved boston scientific corporation neurostimulator for pain. positive trials, subjects with a successful trial outcome, may progress to permanent implant of a neurostimulation system. individualization of neurostimulation therapy for pain will be determined according to investigator discretion and site routine care, and in accordance with inclusion and exclusion criteria.

Eligibility criteria:
key inclusion criteria: * study candidate is scheduled to be trialed, on-label, with a commercially approved boston scientific neurostimulation system for pain, per local directions for use * signed a valid, irb/ec-approved informed consent form * 18 years of age or older key exclusion criteria: * contraindicated for boston scientific neurostimulation system * currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments

Keywords: stimulation implantable pulse generator back pain chronic pain leg pain
voriconazole and caspofungin acetate in treating invasive fungal infections in patients with weakened immune systems

Conditions: Infection; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: voriconazole and caspofungin acetate may control invasive fungal infections in patients who have weakened immune systems. purpose: this phase ii trial is studying how well giving voriconazole together with caspofungin acetate works in treating invasive fungal infections in patients with weakened immune systems.

objectives: primary * determine the 12-week complete and partial response rate in immunocompromised patients with invasive fungal infections treated with voriconazole and caspofungin acetate. secondary * determine the 12-week survival rate in patients treated with this regimen. * determine the safety of this regimen in these patients. outline: patients receive voriconazole orally or iv over 1 hour twice daily and caspofungin acetate iv over 1 hour once daily on days 1-84. treatment continues in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 47 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of probable or definite invasive fungal infection with 1 of the following organisms: * aspergillus species * fusarium species * scedosporium species (pseudallescheria boydii) * other dematiaceous molds * the following diagnosis are not allowed: * zygomycetes (mucor or rhizopus species) * chronic aspergillosis * aspergilloma * allergic bronchopulmonary aspergillosis * must be immunocompromised patient characteristics: age * 18 and over performance status * not specified life expectancy * at least 72 hours hematopoietic * not specified hepatic * ast \< 5 times upper limit of normal (uln) * bilirubin \< 5 times uln * alkaline phosphatase \< 5 times uln * no child-pugh class c cirrhosis renal * creatinine clearance ≥ 50 ml/min pulmonary * no mechanical ventilation other * not pregnant or nursing * fertile patients must use effective contraception * no hypersensitivity to azoles, caspofungin acetate, or their components * no history of galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified other * more than 14 days since prior therapeutic antifungal therapy of ≥ 1 week duration * more than 14 days since prior and no concurrent administration of any of the following medications: * terfenadine * astemizole * cisapride * pimozide * quinidine * sirolimus * rifampin * carbamazepine * long-acting barbiturates * rifabutin * ergot alkaloids (i.e., ergotamine and dihydroergotamine)

Keywords: infection unspecified adult solid tumor, protocol specific
visual performance following implantation of presbyopia correcting iols

Conditions: Loss of Visual Contrast Sensitivity; Near Vision; Visual Impairment

Summary: the purpose of the current study was to compare the visual performance after bilateral implantation of the panoptix iol , or the at lisa iol or tecnis symfony iol . the focus was on intermediate vision, defocus curves, and contrast sensitivity.


Eligibility criteria:
inclusion criteria: * patients with normal ocular examination apart from cataract. exclusion criteria: * previous ocular surgery. * ocular pathology or corneal abnormalities. * an endothelial cell count below 2000 cells/mm2. * corneal astigmatism greater than 1.0 diopter (d) measured with scheimpflug tomography (sirius, cso, italy).
cck1r function in patient leukocytes

Conditions: Obesity; Diabetes Mellitus, Type 2; Metabolic Syndrome

Summary: the type 1 cholecystokinin receptor (cck1r) is a potential target for the treatment of obesity, due to the ability of this gi hormone to elicit satiety. however, this receptor has been shown to be sensitive to the cholesterol content of the membrane in which it is expressed. because some patients who might be candidates for the use of cck agonists to treat their obesity and co-morbidities, the goal of this study is to determine how metabolic abnormalities might affect the responsiveness of this receptor to cck. because the normal site mediating cck-stimulated satiety is on vagal afferent neurons that cannot easily be studied, we will collect buffy coat cells from a peripheral blood sample from patients involved in the sangre por salud biobank at mountain park medical center. ex vivo, the cck1r will be expressed on these cells and will be functionally characterized, and the cholesterol content of the cells will be assayed. these data will be correlated with the clinical, biochemical, and metabolic phenotypic data collected as part of the parent study.

subjects are volunteers who provide prospective informed consent to be entered into the sangre por salud biobank at mountain park medical center. these include men and women age 18-85 of hispanic/latino descent, who are not pregnant or have given birth in the previous 12 months, or who are nursing, and who have not been diagnosed with cancer in the previous three years. two groups of patients are included, representing those who have not been diagnosed as having diabetes, and those with diabetes. subjects undergo entry physical examination and standard metabolic phenotyping, with the non-diabetics also undergoing a 2-hour glucose tolerance test. blood samples are also banked and available for other studies, such as the one now being described. for the current study, 5 ml of blood will be coded and delivered in an anonymized form. buffy coat cells will be isolated and infected ex vivo with a viral construct including the wild type cck1r tagged with a fluorescent tag. cells will be placed in culture overnight and harvested for quantitation of receptor expression and determination of cck responsiveness and cholesterol content. these data will be correlated with selected relevant clinical, biochemical, and morphometric data.

Eligibility criteria:
inclusion criteria: * volunteers exclusion criteria: * hispanic/latino descent not pregnant, or given birth in the previous 12 months, or currently nursing not diagnosed with cancer in the past three years